Summary

Point-of-Care Molecular Diagnostics Market Summary

The global point of care molecular diagnostics market size was estimated at USD 8.22 billion in 2024 and is projected to reach USD 14.47 billion by 2033, growing at a CAGR of 6.52% from 2025 to 2033. This market focuses on rapid and accurate molecular testing conducted near the patient, enabling timely clinical decision-making. These platforms are used across various applications, particularly in infectious disease detection, respiratory illnesses, and sexually transmitted infections.

Market growth is driven by the rising demand for decentralized testing, especially in resource-limited settings and emergency care environments. The increasing burden of infectious diseases and the need for rapid turnaround time have expanded the adoption of point-of-care molecular technologies. Technological advances in microfluidics, isothermal amplification, and portable PCR systems are enhancing the accuracy and usability of these diagnostics. In addition, post-pandemic healthcare priorities emphasize rapid response testing, further supporting market expansion.

Moreover, POC molecular diagnostics in primary care settings range from simple glucose testing to complex coagulation testing. In several clinics, professionals are switching to POC testing from conventional lab testing, which helps shorten the time taken to decide whether further tests are required by avoiding delays during specimen preparation and transport. Other advantages of POC molecular diagnostics are rapid availability of results, lower costs, and better outcomes. The point of care molecular diagnostics industry has grown rapidly in the past few years, especially in the U.S. and European countries, owing to increased awareness regarding various issues such as medical & organizational concerns and economic advantages of POCT.

Aging is influenced by the interaction of several environmental and genetic factors and is characterized as the single most substantial risk factor for cancer development. Based on the U.S. National Cancer Institute’s Surveillance Epidemiology and End Results (SEER) Database, 38% of women and 43% of men are estimated to develop cancer during their lifetime. Nearly two-thirds of all new cancer cases are diagnosed in people aged 65 and above, which highlights that aging can make people more vulnerable to cancer. This is where molecular diagnostics play an important role, as it has a tremendous impact on the management of cancer, infectious diseases, and cardiovascular diseases. It is, therefore, vital for public health surveillance and detection. Thus, the growing geriatric population is expected to drive market growth.

Moreover, market players are continuously involved in the development of novel POC testing products to capitalize on market opportunities. For instance, in February 2023, Huwel Lifesciences designed a portable RT-PCR machine to test types of viruses. The company claimed that the test takes around 30 minutes and can be used to detect respiratory and other infections using blood and gastrointestinal samples. Moreover, in April 2023, Curative, Inc. announced the spin-off of Sensible Diagnostics, focusing on the commercialization of a novel POC PCR testing platform to provide results within 10 minutes with high accuracy.

Global Point Of Care Molecular Diagnostics Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global point of care molecular diagnostics market report based on application, technology, test location, end-use, and region:

• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• PCR-based
• Genetic Sequencing-based
• Hybridization-based
• Microarray-based
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Infectious Diseases
o HIV POC
o Clostridium difficile POC
o HBV POC
o Pneumonia or Streptococcus associated infections
o Respiratory syncytial virus (RSV) POC
o HPV POC
o Influenza/Flu POC
o HCV POC
o MRSA POC
o TB and drug-resistant TB POC
o HSV POC
o Other Infectious Diseases
• Oncology
• Hematology
• Prenatal Testing
• Endocrinology
• Other Applications
• Test Location Outlook (Revenue, USD Million, 2021 - 2033)
• OTC
• POC
• End-use Outlook (Revenue, USD Million, 2021 - 2033)
• Decentralized Labs
• Hospitals
• Home-care
• Assisted Living Healthcare Facilities
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Denmark
o Sweden
o Norway
• Asia Pacific
o Japan
o China
o India
o Australia
o South Korea
o Thailand
• Latin America
o Brazil
o Argentina
• Middle East and Africa (MEA)
o South Africa
o Saudi Arabia
o UAE
o Kuwait

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation
1.1.1. Market Definitions
1.2. Objectives
1.2.1. Objective - 1
1.2.2. Objective - 2
1.2.3. Objective - 3
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. GVR’s Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.5. Information or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity Flow Analysis
1.8. List of Secondary Sources
1.9. List of Abbreviations
1.10. List of Primary Sources
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Dynamics
3.4. Market Drivers
3.4.1. Growing Demand for Rapid and Decentralized Testing
3.4.2. Rising Prevalence of Infectious Diseases
3.4.3. Technological Advancements in Molecular Platforms
3.5. Market Restraint Analysis
3.5.1. High Cost of Molecular POC Devices and Consumables
3.5.2. Regulatory and Quality Assurance Challenges
3.6. Business Environment Analysis
3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
3.6.2. Porter’s Five Forces Analysis
3.6.3. COVID-19 Impact Analysis
Chapter 4. Technology Business Analysis
4.1. Point-of-Care Molecular Diagnostics Market: Technology Movement Analysis
4.2. PCR-based
4.2.1. PCR-based Market, 2021 - 2033 (USD Million)
4.3. Genetic Sequencing-based
4.3.1. Genetic Sequencing-based Market, 2021 - 2033 (USD Million)
4.4. Hybridization-based
4.4.1. Hybridization-based Market, 2021 - 2033 (USD Million)
4.5. Microarray-based
4.5.1. Microarray-based Market, 2021 - 2033 (USD Million)
Chapter 5. Application Business Analysis
5.1. Point-of-Care Molecular Diagnostics Market: Application Movement Analysis
5.2. Infectious Diseases
5.2.1. Infectious Diseases Market, 2021 - 2033 (USD Million)
5.2.2. HIV POC
5.2.2.1. HIV POC Market, 2021 - 2033 (USD Million)
5.2.3. Clostridium difficile POC
5.2.3.1. Clostridium difficile POC Market, 2021 - 2033 (USD Million)
5.2.4. HBV POC
5.2.4.1. HBV POC Market, 2021 - 2033 (USD Million)
5.2.5. Pneumonia or Streptococcus associated infections
5.2.5.1. Pneumonia or Streptococcus associated infections Market, 2021 - 2033 (USD Million)
5.2.6. Respiratory Syncytial Virus (RSV) POC
5.2.6.1. Respiratory Syncytial Virus (RSV) POC Market, 2021 - 2033 (USD Million)
5.2.7. HPV POC
5.2.7.1. HPV POC Market, 2021 - 2033 (USD Million)
5.2.8. Influenza/Flu POC
5.2.8.1. Influenza/Flu POC Market, 2021 - 2033 (USD Million)
5.2.9. HCV POC
5.2.9.1. HCV POC Market, 2021 - 2033 (USD Million)
5.2.10. MRSA POC
5.2.10.1. MRSA POC Market, 2021 - 2033 (USD Million)
5.2.11. TB and drug-resistant TB POC
5.2.11.1. TB and drug-resistant TB POC Market, 2021 - 2033 (USD Million)
5.2.12. HSV POC
5.2.12.1. HSV POC Market, 2021 - 2033 (USD Million)
5.2.13. Other Infectious Diseases
5.2.13.1. Other Infectious Diseases Market, 2021 - 2033 (USD Million)
5.3. Oncology
5.3.1. Oncology Market, 2021 - 2033 (USD Million)
5.4. Hematology
5.4.1. Hematology Market, 2021 - 2033 (USD Million)
5.5. Prenatal Testing
5.5.1. Prenatal Testing Market, 2021 - 2033 (USD Million)
5.6. Endocrinology
5.6.1. Endocrinology Market, 2021 - 2033 (USD Million)
5.7. Others
5.7.1. Others Market, 2021 - 2033 (USD Million)
Chapter 6. Test Location Business Analysis
6.1. Point-of-Care Molecular Diagnostics Market: Test Location Movement Analysis
6.2. OTC
6.2.1. OTC Market, 2021 - 2033 (USD Million)
6.3. POC
6.3.1. POC Market, 2021 - 2033 (USD Million)
Chapter 7. End Use Business Analysis
7.1. Point-of-Care Molecular Diagnostics Market: End Use Movement Analysis
7.2. Decentralized Labs
7.2.1. Decentralized Labs Market, 2021 - 2033 (USD Million)
7.3. Hospitals
7.3.1. Hospitals Market, 2021 - 2033 (USD Million)
7.4. Homecare
7.4.1. Home-care Market, 2021 - 2033 (USD Million)
7.5. Assisted Living Healthcare Facilities
7.5.1. Assisted Living Healthcare Facilities Market, 2021 - 2033 (USD Million)
7.6. Others
7.6.1. Others Market, 2021 - 2033 (USD Million)
Chapter 8. Regional Business Analysis
8.1. Point-of-Care Molecular Diagnostics Market Share By Region, 2024 & 2033
8.2. North America
8.2.1. North America Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
8.2.2. U.S.
8.2.2.1. Key Country Dynamics
8.2.2.2. Target Disease Prevalence
8.2.2.3. Competitive Scenario
8.2.2.4. Regulatory Framework
8.2.2.5. Reimbursement Scenario
8.2.2.6. U.S. Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD MILLION)
8.2.3. Canada
8.2.3.1. Key Country Dynamics
8.2.3.2. Target Disease Prevalence
8.2.3.3. Competitive Scenario
8.2.3.4. Regulatory Framework
8.2.3.5. Reimbursement Scenario
8.2.3.6. Canada Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
8.2.4. Mexico
8.2.4.1. Key Country Dynamics
8.2.4.2. Target Disease Prevalence
8.2.4.3. Competitive Scenario
8.2.4.4. Regulatory Framework
8.2.4.5. Reimbursement Scenario
8.2.4.6. Mexico Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
8.3. Europe
8.3.1. Europe Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
8.3.2. Germany
8.3.2.1. Key Country Dynamics
8.3.2.2. Target Disease Prevalence
8.3.2.3. Competitive Scenario
8.3.2.4. Regulatory Framework
8.3.2.5. Reimbursement Scenario
8.3.2.6. Germany Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
8.3.3. UK
8.3.3.1. Key Country Dynamics
8.3.3.2. Target Disease Prevalence
8.3.3.3. Competitive Scenario
8.3.3.4. Regulatory Framework
8.3.3.5. Reimbursement Scenario
8.3.3.6. UK Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
8.3.4. France
8.3.4.1. Key Country Dynamics
8.3.4.2. Target Disease Prevalence
8.3.4.3. Competitive Scenario
8.3.4.4. Regulatory Framework
8.3.4.5. Reimbursement Scenario
8.3.4.6. France Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
8.3.5. Italy
8.3.5.1. Key Country Dynamics
8.3.5.2. Target Disease Prevalence
8.3.5.3. Competitive Scenario
8.3.5.4. Regulatory Framework
8.3.5.5. Reimbursement Scenario
8.3.5.6. Italy Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
8.3.6. Spain
8.3.6.1. Key Country Dynamics
8.3.6.2. Target Disease Prevalence
8.3.6.3. Competitive Scenario
8.3.6.4. Regulatory Framework
8.3.6.5. Reimbursement Scenario
8.3.6.6. Spain Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
8.3.7. Denmark
8.3.7.1. Key Country Dynamics
8.3.7.2. Target Disease Prevalence
8.3.7.3. Competitive Scenario
8.3.7.4. Regulatory Framework
8.3.7.5. Reimbursement Scenario
8.3.7.6. Denmark Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
8.3.8. Sweden
8.3.8.1. Key Country Dynamics
8.3.8.2. Target Disease Prevalence
8.3.8.3. Competitive Scenario
8.3.8.4. Regulatory Framework
8.3.8.5. Reimbursement Scenario
8.3.8.6. Sweden Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
8.3.9. Norway
8.3.9.1. Key Country Dynamics
8.3.9.2. Target Disease Prevalence
8.3.9.3. Competitive Scenario
8.3.9.4. Regulatory Framework
8.3.9.5. Reimbursement Scenario
8.3.9.6. Norway Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
8.4. Asia Pacific
8.4.1. Asia Pacific Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
8.4.2. Japan
8.4.2.1. Key Country Dynamics
8.4.2.2. Target Disease Prevalence
8.4.2.3. Competitive Scenario
8.4.2.4. Regulatory Framework
8.4.2.5. Reimbursement Scenario
8.4.2.6. Japan Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
8.4.3. China
8.4.3.1. Key Country Dynamics
8.4.3.2. Target Disease Prevalence
8.4.3.3. Competitive Scenario
8.4.3.4. Regulatory Framework
8.4.3.5. Reimbursement Scenario
8.4.3.6. China Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
8.4.4. India
8.4.4.1. Key Country Dynamics
8.4.4.2. Target Disease Prevalence
8.4.4.3. Competitive Scenario
8.4.4.4. Regulatory Framework
8.4.4.5. Reimbursement Scenario
8.4.4.6. India Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
8.4.5. South Korea
8.4.5.1. Key Country Dynamics
8.4.5.2. Target Disease Prevalence
8.4.5.3. Competitive Scenario
8.4.5.4. Regulatory Framework
8.4.5.5. Reimbursement Scenario
8.4.5.6. South Korea Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
8.4.6. Australia
8.4.6.1. Key Country Dynamics
8.4.6.2. Target Disease Prevalence
8.4.6.3. Competitive Scenario
8.4.6.4. Regulatory Framework
8.4.6.5. Reimbursement Scenario
8.4.6.6. Australia Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
8.4.7. Thailand
8.4.7.1. Key Country Dynamics
8.4.7.2. Target Disease Prevalence
8.4.7.3. Competitive Scenario
8.4.7.4. Regulatory Framework
8.4.7.5. Reimbursement Scenario
8.4.7.6. Thailand Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
8.5. Latin America
8.5.1. Latin America Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
8.5.2. Brazil
8.5.2.1. Key Country Dynamics
8.5.2.2. Target Disease Prevalence
8.5.2.3. Competitive Scenario
8.5.2.4. Regulatory Framework
8.5.2.5. Reimbursement Scenario
8.5.2.6. Brazil Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
8.5.3. Argentina
8.5.3.1. Key Country Dynamics
8.5.3.2. Target Disease Prevalence
8.5.3.3. Competitive Scenario
8.5.3.4. Regulatory Framework
8.5.3.5. Reimbursement Scenario
8.5.3.6. Argentina Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
8.6. MEA
8.6.1. MEA Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
8.6.2. South Africa
8.6.2.1. Key Country Dynamics
8.6.2.2. Target Disease Prevalence
8.6.2.3. Competitive Scenario
8.6.2.4. Regulatory Framework
8.6.2.5. Reimbursement Scenario
8.6.2.6. South Africa Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
8.6.3. Saudi Arabia
8.6.3.1. Key Country Dynamics
8.6.3.2. Target Disease Prevalence
8.6.3.3. Competitive Scenario
8.6.3.4. Regulatory Framework
8.6.3.5. Reimbursement Scenario
8.6.3.6. Saudi Arabia Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
8.6.4. UAE
8.6.4.1. Key Country Dynamics
8.6.4.2. Target Disease Prevalence
8.6.4.3. Competitive Scenario
8.6.4.4. Regulatory Framework
8.6.4.5. Reimbursement Scenario
8.6.4.6. UAE Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
8.6.5. Kuwait
8.6.5.1. Key Country Dynamics
8.6.5.2. Target Disease Prevalence
8.6.5.3. Competitive Scenario
8.6.5.4. Regulatory Framework
8.6.5.5. Reimbursement Scenario
8.6.5.6. Kuwait Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
Chapter 9. Competitive Landscape
9.1. Participant’s overview
9.2. Financial performance
9.3. Participant categorization
9.3.1. Market Leaders
9.3.2. Point-of-Care Molecular Diagnostics Market Share Analysis, 2023
9.3.3. Company Profiles
9.3.3.1. Abbott
9.3.3.1.1. Company Overview
9.3.3.1.2. Financial Performance
9.3.3.1.3. Product Benchmarking
9.3.3.1.4. Strategic Initiatives
9.3.3.2. Bayer AG
9.3.3.2.1. Company Overview
9.3.3.2.2. Financial Performance
9.3.3.2.3. Product Benchmarking
9.3.3.2.4. Strategic Initiatives
9.3.3.3. F. Hoffmann-La Roche AG
9.3.3.3.1. Company Overview
9.3.3.3.2. Financial Performance
9.3.3.3.3. Product Benchmarking
9.3.3.3.4. Strategic Initiatives
9.3.3.4. Nova Biomedical
9.3.3.4.1. Company Overview
9.3.3.4.2. Financial Performance
9.3.3.4.3. Product Benchmarking
9.3.3.4.4. Strategic Initiatives
9.3.3.5. QIAGEN
9.3.3.5.1. Company Overview
9.3.3.5.2. Financial Performance
9.3.3.5.3. Product Benchmarking
9.3.3.5.4. Strategic Initiatives
9.3.3.6. Nipro Diagnostics
9.3.3.6.1. Company Overview
9.3.3.6.2. Financial Performance
9.3.3.6.3. Product Benchmarking
9.3.3.6.4. Strategic Initiatives
9.3.3.7. Danaher
9.3.3.7.1. Company Overview
9.3.3.7.2. Financial Performance
9.3.3.7.3. Product Benchmarking
9.3.3.7.4. Strategic Initiatives
9.3.3.8. Bio-Rad Laboratories, Inc.
9.3.3.8.1. Company Overview
9.3.3.8.2. Financial Performance
9.3.3.8.3. Product Benchmarking
9.3.3.8.4. Strategic Initiatives
9.3.3.9. bioMérieux
9.3.3.9.1. Company Overview
9.3.3.9.2. Financial Performance
9.3.3.9.3. Product Benchmarking
9.3.3.9.4. Strategic Initiatives
9.3.3.10. Agilent Technologies, Inc.
9.3.3.10.1. Company Overview
9.3.3.10.2. Financial Performance
9.3.3.10.3. Product Benchmarking
9.3.3.10.4. Strategic Initiatives
9.3.3.11. Abaxis
9.3.3.11.1. Company Overview
9.3.3.11.2. Financial Performance
9.3.3.11.3. Product Benchmarking
9.3.3.11.4. Strategic Initiatives
9.3.3.12. OraSure Technologies
9.3.3.12.1. Company Overview
9.3.3.12.2. Financial Performance
9.3.3.12.3. Product Benchmarking
9.3.3.12.4. Strategic Initiatives
9.3.4. Strategy Mapping
9.3.4.1. Expansion
9.3.4.2. Acquisition
9.3.4.3. Collaborations
9.3.4.4. Disease Type/Drug Class Launch
9.3.4.5. Partnerships
9.3.4.6. Others